Sugi Predict

Sugi Predict / Compounds / SCHEMBL14286281

SCHEMBL14286281

SCHEMBL14286281

Cc1cc(C(=O)Nc2ccc(C)c(Nc3nc(-c4cccnc4)cs3)c2)ccc1CN1CCN(C)CC1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 16/20 0.84
▸ BCR P11274 14/20 0.84
▸ KIT P10721 7/20 0.84
▸ LYN P07948 6/20 0.84
▸ CSF1R P07333 4/20 0.84
▸ PDGFRB P09619 3/20 0.84
▸ PDGFRA P16234 3/20 0.84
▸ EGFR P00533 3/20 0.84
▸ BRAF P15056 3/20 0.84
▸ ERBB2 P04626 2/20 0.84
▸ LCK P06239 2/20 0.84
▸ FYN P06241 2/20 0.84
▸ FGR P09769 2/20 0.84
▸ SRC P12931 2/20 0.84
▸ NQO2 P16083 2/20 0.84
▸ EPHA8 P29322 2/20 0.84
▸ ABL2 P42684 2/20 0.84
▸ FRK P42685 2/20 0.84
▸ BLK P51451 2/20 0.84
▸ DDR1 Q08345 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833019 0.94 ABL1 (0.80) ABL1BCRKITLYNCSF1R
SCHEMBL717080 0.94 ABL1 (0.80) ABL1BCRKITLYNCSF1R
SCHEMBL716627 0.94 ABL1 (0.80) ABL1BCRKITLYNCSF1R
SCHEMBL719085 0.94 ABL1 (0.83) ABL1BCRKITLYNCSF1R
SCHEMBL14286285 0.93 ABL1 (0.71) ABL1BCRKITLYNCSF1R
SCHEMBL4830586 0.92 KIT (0.77) ABL1BCRKITLYNCSF1R
Masitinib SCHEMBL29355443 0.91 ABL1 (1.00) ABL1BCRKITLYNCSF1R
Masitinib SCHEMBL717239 0.91 ABL1 (1.00) ABL1BCRKITLYNCSF1R
Masitinib SCHEMBL29353195 0.91 ABL1 (1.00) ABL1BCRKITLYNCSF1R
SCHEMBL3301373 0.90 ABL1 (0.91) ABL1BCRKITLYNCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis AB SCIENCE 2008-01-31 — — US disclosed
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis AB SCIENCE 2008-01-31 — — US disclosed
US-20070191267-A1 Use of tyrosine kinase inhibitors for treating cerebral ischemia AB SCIENCE 2007-08-16 — — US disclosed
US-20070191267-A1 Use of tyrosine kinase inhibitors for treating cerebral ischemia AB SCIENCE 2007-08-16 — — US disclosed
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 — — US disclosed
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes KIT, CPA3, CMA1 ABL1 233/4885BCR 3609/4885KIT 1/4885
US-20070191267-A1 Use of tyrosine kinase inhibitors for treating cerebral ischemia KIT, MAST3, CPA3 ABL1 14/4885BCR 2136/4885KIT 1/4885
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis KIT, CMA1, CPA3 ABL1 8/4885BCR 41/4885KIT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.